20 results on '"Reese PR"'
Search Results
2. PRK13 REGIONAL SIMILARITIES IN IMPROVEMENT AND PERSISTENCE OF SHORT-TERM HEALTH-RELATED QUALITY OF LIFE EFFECT OF TOLTERODINE ON OVERACTIVE BLADDER PATIENTS
- Author
-
Pleil, AM, primary, Burgess, SM, additional, Reese, PR, additional, and Kelleher, CJ, additional
- Published
- 2002
- Full Text
- View/download PDF
3. PUK11 EFFECTS OF LONG-TERM TOLTERODINE TREATMENT ON PHYSICAL AND SYMPTOM ASPECTS OF HEALTH-RELATED QUALITY OF LIFE IN OVERACTIVE BLADDER PATIENTS
- Author
-
Okano, GJ, primary, Pleil, AM, additional, Reese, PR, additional, and Kelleher, CJ, additional
- Published
- 2002
- Full Text
- View/download PDF
4. How much is enough and who says so? The case of the King's Health Questionnaire and overactive bladder.
- Author
-
Kelleher CJ, Pleil AM, Reese PR, Burgess SM, and Brodish PH
- Published
- 2004
- Full Text
- View/download PDF
5. The validation of patient-related global assessments of treatment benefit, satisfaction, and willingness to continue -- the BSW.
- Author
-
Pleil AM, Coyne KS, Reese PR, Jumadilova Z, Rovner ES, and Kelleher CJ
- Published
- 2005
- Full Text
- View/download PDF
6. Validation of a Health-Related Quality of Life Questionnaire in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Phase 3 Randomized Trial.
- Author
-
Lapin B, Garey KW, Wu H, Pham SV, Huang SP, Reese PR, Wang E, and Deshpande A
- Subjects
- Humans, Female, Adolescent, Male, Quality of Life, Reproducibility of Results, Surveys and Questionnaires, Recurrence, Clostridium Infections drug therapy, Clostridioides difficile
- Abstract
Background: Debilitating symptoms of recurrent Clostridioides difficile infection (rCDI) often lead to long-term effects on health-related quality-of-life (HRQOL). In ECOSPOR III, SER-109, an investigational oral microbiome therapeutic, was superior to placebo in reducing rCDI. We investigated the validity, reliability, and responsiveness of a 32-item, CDI-specific questionnaire-the Clostridium difficile Quality of Life Survey (Cdiff32)-across mental, physical, and social domains in patients with rCDI., Methods: In this post hoc analysis of a phase 3 clinical trial, 182 outpatients with rCDI completed Cdiff32 and EQ-5D at baseline and at 1 and 8 weeks. Cdiff32 was evaluated for item performance, internal reliability, and convergent validity. To assess known-groups validity, Cdiff32 scores were compared by disease recurrence status at week 1; internal responsiveness was evaluated in the nonrecurrent disease group by 8 weeks by means of paired t test., Results: All 182 patients (mean age [standard deviation], 65.5 [16.5] years; 59.9% female) completed baseline Cdiff32. Confirmatory factor analysis identified 3 domains (physical, mental, and social relationships) with good item fit. High internal reliability was demonstrated (Cronbach α = 0.94 with all subscales >0.80). Convergent validity was evidenced by significant correlations between Cdiff32 subscales and EQ-5D (r = 0.29-0.37; P < .001). Cdiff32 differentiated patients by disease recurrence status at week 1 (effect sizes, 0.38-0.42; P < .05 overall), with significant improvement from baseline through week 8 in patients with nonrecurrent disease at week 1 (effect sizes, 0.75-1.02; P < .001 overall)., Conclusions: Cdiff32 is a valid, reliable, and responsive disease-specific HRQOL questionnaire that is fit for purpose for interventional treatment trials. The significant improvement in patients with nonrecurrent disease by 8 weeks demonstrates the negative impact of rCDI on HRQOL., Competing Interests: Potential conflicts of interest. B. L. reports payments to self for being on the editorial board of Quality of Life Research, Anesthesia & Analgesia, and Chest. K. W. G. reports grants or contracts from Seres Health, Paratek Pharmaceuticals, Acurx Pharmaceuticals, and Summit Pharmaceuticals, all outside the submitted work. S. V. P., S. P. H., and P. R. R. are health economics and outcomes research (HEOR) consultants (at AESARA) for Seres Therapeutics. P. R. R. reports being a freelance consultant paid by Aesara to provide consulting support to Seres Therapeutics. E. W. reports employee stock options from Seres Therapeutics. A. D. is a consultant for Merck, has received research funding from The Clorox Company, and reports personal stocks from Seres Therapeutics. H. W. reports no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
7. Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109: Secondary Analysis of a Randomized Clinical Trial.
- Author
-
Garey KW, Jo J, Gonzales-Luna AJ, Lapin B, Deshpande A, Wang E, Hasson B, Pham SV, Huang SP, Reese PR, Wu H, Hohmann E, Feuerstadt P, Oneto C, Berenson CS, Lee C, McGovern B, and vonMoltke L
- Subjects
- Humans, Female, Aged, Male, Anti-Bacterial Agents therapeutic use, Surveys and Questionnaires, Canada, Quality of Life, Clostridium Infections drug therapy
- Abstract
Importance: Recurrent Clostridioides difficile infection (CDI) is a debilitating disease leading to poor health-related quality of life (HRQOL), loss of productivity, anxiety, and depression. The potential association of treatment with HRQOL has not been well evaluated., Objectives: To explore the association of SER-109 compared with placebo on HRQOL in patients with recurrent CDI up to week 8., Design, Setting, and Participants: This study was a secondary analysis of a randomized, double-blind, placebo-controlled trial that took place at 56 sites in the US and Canada from July 2017 to April 2020 and included 182 patients randomized to SER-109 or placebo groups., Interventions: SER-109 or placebo (4 capsules once daily for 3 days) following antibiotics for CDI., Main Outcomes and Measures: Exploratory analysis of HRQOL using the disease specific Clostridioides difficile Quality of Life Survey (Cdiff32) assessed at baseline, week 1, and week 8., Results: In this study, 182 patients (109 [59.9%] female; mean age, 65.5 [16.5] years) were randomized to SER-109 (89 [48.9%]) or placebo (93 [51.1%]) groups and were included in the primary and exploratory analyses. Baseline Cdiff32 scores were similar between patients in the SER-109 and placebo groups (52.0 [18.3] vs 52.8 [18.7], respectively). The proportion of patients with overall improvement from baseline in the Cdiff32 total score was higher in the SER-109 arm than placebo at week 1 (49.4% vs 26.9%; P = .012) and week 8 (66.3% vs 48.4%; P = .001).Greater improvements in total and physical domain and subdomain scores were observed in patients in the SER-109 group compared with placebo as early as week 1, with continued improvements observed at week 8. Among patients in the placebo group, improvements in HRQOL were primarily observed in patients with nonrecurrent CDI while patients in the SER-109 group reported improvements in HRQOL, regardless of clinical outcome., Conclusions and Relevance: In this secondary analysis of a phase 3 clinical trial, SER-109, an investigational microbiome therapeutic was associated with rapid and steady improvement in HRQOL compared with placebo through 8 weeks, an important patient-reported outcome., Trial Registration: ClinicalTrials.gov Identifier: NCT03183128.
- Published
- 2023
- Full Text
- View/download PDF
8. Feasibility of an online mindfulness program for stress management--a randomized, controlled trial.
- Author
-
Morledge TJ, Allexandre D, Fox E, Fu AZ, Higashi MK, Kruzikas DT, Pham SV, and Reese PR
- Subjects
- Adaptation, Psychological, Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Patient Dropouts psychology, Quality of Life psychology, Internet, Mindfulness, Stress, Psychological therapy, Therapy, Computer-Assisted
- Abstract
Background: Chronic stress affects many Americans. Stress management programs may be prohibitively expensive or have limited access., Purpose: This study aims to determine feasibility of an 8-week Internet-based stress management program (ISM) based on mindfulness principles in reducing stress in a 12-week, parallel, randomized, controlled trial., Methods: Participants were randomly allocated to ISM, ISM plus online message board (ISM+), or control groups. Perceived stress, mindfulness, self-transcendence, psychological well-being, vitality, and quality of life were measured at baseline, week 8, and week 12 using standard validated questionnaires., Results: ISM and ISM+ groups demonstrated statistically significant improvements compared with control on all measures except vitality and physical health., Conclusions: The ISM program effectively and sustainably reduced measures of stress. The magnitude of improvement is comparable to traditional mindfulness programs, although fewer participants were engaged. This feasibility study provides strong support for online stress management programs, which increase access at a fraction of cost of traditional programs.
- Published
- 2013
- Full Text
- View/download PDF
9. Asthma patients prefer Respimat Soft Mist Inhaler to Turbuhaler.
- Author
-
Hodder R, Reese PR, and Slaton T
- Subjects
- Administration, Inhalation, Adult, Asthma physiopathology, Double-Blind Method, Equipment Design, Female, Humans, Least-Squares Analysis, Male, Middle Aged, Psychometrics, Severity of Illness Index, Surveys and Questionnaires, Treatment Outcome, Asthma drug therapy, Bronchodilator Agents administration & dosage, Budesonide administration & dosage, Nebulizers and Vaporizers, Patient Preference, Patient Satisfaction
- Abstract
Device satisfaction and preference are important patient-reported outcomes to consider when choosing inhaled therapy. A subset of adults (n = 153) with moderate or severe asthma participating in a randomized parallel-group, double-dummy trial that compared the efficacy and safety of 12 weeks' treatment with budesonide delivered via Respimat Soft Mist Inhaler (SMI) (200 or 400 microg bd) or Turbuhaler dry powder inhaler (400 microg bd), completed a questionnaire on patient device preference and satisfaction (PASAPQ) as part of a psychometric validation. As the study used a double-dummy design to maintain blinding, patients used and assessed both devices, rating their satisfaction with, preference for, and willingness to continue using each device. The mean age of patients was 41 years, 69% were female and the mean duration of disease was 16 years. Total PASAPQ satisfaction scores were 85.5 and 76.9 for Respimat SMI and Turbuhaler respectively (p < 0.0001); 112 patients (74%) preferred Respimat SMI and 26 (17%) preferred Turbuhaler. Fourteen subjects (9%) indicated no preference for either inhaler. Willingness to continue using Respimat SMI was higher than that for Turbuhaler (mean scores: 80/100 and 62/100, respectively). Respimat SMI was preferred to Turbuhaler by adult asthma patients who used both devices in a clinical trial setting.
- Published
- 2009
- Full Text
- View/download PDF
10. Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence.
- Author
-
Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, and Barron RL
- Subjects
- Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Injections, Intramuscular, Male, Middle Aged, Surveys and Questionnaires, Treatment Outcome, Urinary Bladder, Urinary Bladder, Neurogenic psychology, Botulinum Toxins, Type A administration & dosage, Neuromuscular Agents administration & dosage, Quality of Life, Urinary Bladder, Neurogenic drug therapy
- Abstract
Objective: To evaluate the impact of botulinum toxin type A (BoNTA) on health-related quality of life in patients with neurogenic urinary incontinence (UI) using the Incontinence Quality of Life questionnaire (I-QOL)., Methods: Randomized, double-blind, multicenter, placebo-controlled study involving eight centers across Belgium, France, and Switzerland. Patients (n = 59) with UI due to neurogenic detrusor overactivity (spinal cord injury, n = 53; multiple sclerosis, n = 6) who were inadequately managed on oral anticholinergics received a single dose of BoNTA (200U or 300U, Botox) or placebo. I-QOL scores at screening and after treatment at weeks 2, 6, 12, 18, and 24 were recorded., Results: Median total and subscale I-QOL scores increased significantly from screening with BoNTA 300U compared with placebo at all time points (p<0.05) and with BoNTA 200U compared with placebo at all time points for total score and the Avoidance Limiting Behavior subscale (p<0.05), and at weeks 2, 6, 12, and 18 (p<0.05), but not 24 for the Psychosocial Impact and Social Embarrassment subscales. Approximately twice as many BoNTA recipients as placebo recipients achieved at least a minimal important difference in total I-QOL score at 2, 6, 12, and 24 wk., Conclusions: BoNTA significantly improves UI-associated health-related quality of life in patients with neurogenic UI., (European Association of Urology.)
- Published
- 2007
- Full Text
- View/download PDF
11. Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence.
- Author
-
Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, and Barron R
- Subjects
- Adult, Aged, Botulinum Toxins, Type A therapeutic use, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Multiple Sclerosis complications, Psychometrics methods, Reproducibility of Results, Spinal Cord Injuries complications, Urinary Bladder, Neurogenic drug therapy, Urinary Bladder, Neurogenic etiology, Quality of Life, Surveys and Questionnaires, Urinary Bladder, Neurogenic psychology
- Abstract
Objective: To assess the reliability, validity, responsiveness, and minimally important difference (MID) of the Incontinence Quality of Life (I-QOL) questionnaire in patients with urinary incontinence due to neurogenic detrusor overactivity., Design: Randomized, double-blind, multicenter, placebo-controlled study., Setting: Eight centers across Belgium, France, and Switzerland., Participants: Patients with urinary incontinence due to neurogenic detrusor overactivity inadequately managed on oral anticholinergics. Fifty-nine patients (spinal cord injury, n=53; multiple sclerosis, n=6) were enrolled., Intervention: Single dose of botulinum toxin type A (Botox) (200 or 300 U) or placebo., Main Outcome Measures: I-QOL questionnaire completed at screening and over a 24-week post-treatment period., Results: The Cronbach alpha ranged from .79 to .93, indicating that I-QOL is a reliable measure of QOL in neurogenic urinary incontinence patients. No item had more than 5.1% missing or out of range values. With the exception of 2 items, questions showed acceptable item-scale correlation and scaling success results varied by domain. Post-treatment correlations indicated acceptable construct validity. The I-QOL was responsive to improvements in symptoms. MID values ranged from 4 to 11 points., Conclusions: Results suggest that I-QOL is a reliable, valid, and responsive measure of incontinence-related QOL in neurogenic patients.
- Published
- 2007
- Full Text
- View/download PDF
12. Development and validation of a patient satisfaction and preference questionnaire for inhalation devices.
- Author
-
Kozma CM, Slaton TL, Monz BU, Hodder R, and Reese PR
- Subjects
- Adult, Female, Humans, Male, Psychometrics, Reproducibility of Results, Asthma drug therapy, Nebulizers and Vaporizers, Patient Satisfaction, Pulmonary Disease, Chronic Obstructive drug therapy, Surveys and Questionnaires
- Abstract
Introduction: The Patient Satisfaction and Preference Questionnaire (PASAPQ) is a multi-item measure of respiratory inhalation device satisfaction and preference designed to be easily understood and administered to patients with asthma and COPD. This study assessed its validity, reliability and responsiveness and explored the between-group difference in PASAPQ scores that is meaningful., Methods: The field test version was developed using literature, focus groups and expert opinion. Item reduction followed. The assessment of the validity, reliability and responsiveness of the PASAPQ utilized data from two clinical studies comparing devices delivering the same medication, and was performed with pre-specified criteria. A minimally important difference (MID) was estimated using both anchor- and distribution-based approaches., Results: Two factors of the PASAPQ, 'performance' and 'convenience', were consistent across studies. Missing and out-of-range data were minimal (<1%) and respondents used a full range of response options. All items correlated most highly with their hypothesized scale and all exceeded the minimum correlation criteria of 0.40. Cronbach's alfa was high (0.87-0.94), providing support for internal reliability for the PASAPQ. Correlations of the overall satisfaction item with the performance domain ranged from 0.78 to 0.91, the convenience domain ranged from 0.54 to 0.71, and the total score ranged from 0.78 to 0.90. These moderate-to-strong correlations provide substantial support for the validity of the PASAPQ domains and total score. Discriminate validity was assessed by calculating PASAPQ scores for patients' ratings of the device that they preferred compared with the other, non-preferred device. The preferred device was rated higher on all satisfaction measures, supporting the ability of the PASAPQ to discriminate between preferred and non-preferred devices. Although a difference of 3 or 4 points may be sufficient to observe a small effect difference between groups, most of the MID estimates were in the 8-10 point range., Discussion and Conclusion: Our analyses across asthma, COPD and patients with mixed respiratory disease (with features of both COPD and asthma), study designs and data sets lead us to conclude that the PASAPQ is a practical, valid, reliable and responsive instrument for measuring respiratory device satisfaction. Furthermore, a difference in satisfaction scores between treatment groups of 10 points is, conservatively, a difference that is meaningful to patients.
- Published
- 2005
- Full Text
- View/download PDF
13. How much is enough and who says so?
- Author
-
Kelleher CJ, Pleil AM, Reese PR, Burgess SM, and Brodish PH
- Subjects
- Female, Humans, Male, Quality of Life, Surveys and Questionnaires standards, Urinary Bladder Diseases psychology, Urinary Incontinence psychology
- Abstract
Background: One of the challenges of health-related quality of life research is to translate statistically significant health-related quality of life changes into interpretable clinical or medically important ones., Objective: To calculate the minimal important difference of the King's Health Questionnaire, a condition-specific health-related quality of life questionnaire for the assessment of men and women with lower urinary tract dysfunction., Methods: The King's Health Questionnaire was administered to patients suffering from overactive bladder enrolled in two multinational studies. Minimal important differences were calculated using an anchor-based approach with both a global rating of patient-perceived treatment benefit and one of perceived disease impact. A distribution-based method using effect size was calculated for comparison purposes., Results: Minimal important difference values varied slightly with each method. Using the anchor-based approach, the King's Health Questionnaire minimal important difference ranged between 5-10 points when the calculation factored out patients who reported no change and 6-12 points for patients who experienced a small improvement. The effect size method indicated a minimal important difference of 5 to 6 points for a small effect and 10 to 15 points for a medium effect., Conclusions: In the case of the King's Health Questionnaire, the anchor-based approaches and the distribution-based approach provide similar results. A change from baseline of at least 5 points on King's Health Questionnaire domains indicates a change that is meaningful to patients and is indicative of a clinically meaningful improvement in health-related quality of life after treatment. Convergence of the estimates using different approaches should give us confidence in the values derived for the quality of life domains measured by the King's Health Questionnaire.
- Published
- 2004
- Full Text
- View/download PDF
14. Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder.
- Author
-
Reese PR, Pleil AM, Okano GJ, and Kelleher CJ
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Psychometrics, Quality of Life, Sickness Impact Profile, Surveys and Questionnaires standards, Urination Disorders
- Abstract
Objective: Overactive bladder (OAB) has substantial impact on health-related quality of life (HRQoL). The purpose of this research was to evaluate the psychometric properties of the King's Health Questionnaire (KHQ)., Methods: The KHQ (n = 1284) was administered at baseline and 12 weeks post-treatment in a multinational, double-blind, randomized clinical trial of tolterodine for treatment of OAB. Country-specific psychometric analyses of HRQoL instruments were performed. Countries demonstrating marginal psychometric properties on the KHQ were pooled with same-language countries, re-evaluated, and aggregate analysis performed on the pooled data., Results: Internal consistency of the KHQ was high, item characteristics were good, most assumptions of summed scales were met, and it is externally valid and consistent. Few problems with the KHQ were noted although the performance of the personal relationships domain was complicated by the 'not applicable' response category., Conclusions: Psychometric testing supports the reliability and validity of the KHQ as an OAB-specific measure of HRQoL.
- Published
- 2003
- Full Text
- View/download PDF
15. Screening, prevention and socioeconomic costs associated with the treatment of colorectal cancer.
- Author
-
Redaelli A, Cranor CW, Okano GJ, and Reese PR
- Subjects
- Antineoplastic Agents economics, Antineoplastic Agents therapeutic use, Clinical Trials as Topic, Colorectal Neoplasms diagnosis, Colorectal Neoplasms therapy, Humans, Risk Factors, Colorectal Neoplasms economics, Health Care Costs
- Abstract
Colorectal cancer (CRC), the third most prevalent cancer worldwide, imposes a significant economic and humanistic burden on patients and society. One study conservatively estimated the annual expenditures for colorectal cancer to be approximately dollars US 5.3 billion in 2000, including both direct and indirect costs. However, other investigators estimated inpatient costs alone incurred in the US in 1994 to be around dollars US 5.14 billion. Therefore, the economic burden of colorectal cancer in the US could be projected to be somewhere in the range of dollars US 5.5-6.5 billion by considering that inpatient costs approximate 80% of total direct costs. No worldwide data have been published, but assuming that the US represents 25-40% of total expenditures in oncology, as seen for breast and lung cancers, a rough estimate for colorectal cancer would be in the range of dollars US 14-22 billion. Screening helps increase patient survival by diagnosing colorectal cancer early. The ideal method among the four tests most used (faecal occult blood test, flexible sigmoidoscopy, colonoscopy and double contrast barium enema) has not been identified. Economic studies of colorectal cancer screening are complex because of the many variables involved, as well as the fact that the outcomes must be followed for many years, and the lack of consensus on screening guidelines. Intuitively, modelling colorectal cancer is one way to overcome these hurdles; published modelling studies predict colorectal cancer screening programs to be within the threshold of dollars US 40000 per life-year saved. The faecal occult blood test appears to be the only clearly effective test, both from a clinical and an economic viewpoint. Important limitations are the invasiveness and inconvenience of the screening procedures, except faecal occult blood test. Patients' comfort and satisfaction are essential in improving compliance with screening recommendations, which appears to be low even in the US (35% of the general population aged over 40 years and 60% of the high-risk population), the country with the highest awareness and compliance in the world. Since colorectal cancer is generally a disease of the elderly, its economic burden is expected to grow in the near future, mainly due to population aging. Potential avenues to pursue in order to contain or reduce the economic burden of colorectal cancer would be the design and implementation of efficient screening programmes, the improvement of patient awareness and compliance with screening guidelines, the development of appropriate prevention programs (i.e. primary and secondary), and earlier diagnosis.
- Published
- 2003
- Full Text
- View/download PDF
16. Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder.
- Author
-
Kelleher CJ, Kreder KJ, Pleil AM, Burgess SM, and Reese PR
- Subjects
- Aged, Australia, Benzhydryl Compounds therapeutic use, Cresols therapeutic use, Delayed-Action Preparations, Europe, Female, Humans, Male, Middle Aged, Muscarinic Antagonists therapeutic use, New Zealand, Russia, Surveys and Questionnaires, Tolterodine Tartrate, United States, Urinary Bladder Diseases drug therapy, Urinary Bladder Diseases physiopathology, Urination Disorders physiopathology, Benzhydryl Compounds administration & dosage, Cresols administration & dosage, Muscarinic Antagonists administration & dosage, Phenylpropanolamine, Quality of Life, Urination Disorders drug therapy
- Abstract
Objective: To evaluate the long-term effects of tolterodine on the health-related quality of life (HRQoL) of patients diagnosed with overactive bladder with incontinence., Methods: Patients who completed a 12-week randomized, double-blind, safety and efficacy trial comparing tolterodine with placebo were invited to enroll in a 12-month open-label continuation trial to assess the long-term safety and efficacy of tolterodine. This study reports the HRQoL results from the King's Health Questionnaire (KHQ) and the Short Form-36 (SF-36) that were administered at baseline, at the end of the 12-week trial, and 3 and 12 months following open-label treatment with tolterodine., Results: One thousand seventy-seven patients were included in the intent-to-treat (ITT(B)) population. KHQ translations were available for 838 patients (mean age, 61.1 years; 80.9% women) in the ITT(B) population. HRQoL, as measured by the KHQ, significantly improved from baseline to months 3 and 12 on the following domains: incontinence impact, role limitations, physical limitations, social limitations, personal relationships, emotions, sleep and energy, severity (coping) measures, and symptom severity. Improvements were generally consistent across all analyses for the 3- and 12-month measurements and for the ITT(B) and completer (C(B)) populations. Patients receiving tolterodine in the double-blind study showed additional improvement at the 3-month open-label assessment on all but the general health domain. At 12 months from treatment rollover, all improvements from rollover to 3 months were sustained with additional improvement seen on the incontinence impact and role limitations domains. The general health perceptions domain showed a slight decline from rollover that might be attributable to a natural decline in patients' health status at this life stage. These findings were consistent with other efficacy results whereby efficacy was maintained over the 12-month open-label period. SF-36 results were consistent with previous experience of reduced sensitivity, as population groups were similar to the SF-36 Physical Component and Mental Component scores at various time points and with all populations., Conclusion: Continued treatment with tolterodine provides additional benefits in HRQoL as measured by the KHQ. Of particular importance are improvements on the psychological aspects after longer-term treatment not detected after a short-term trial. Treatment effects on HRQoL are evident even after a 12-week placebo run-in supporting the true clinical effect of active treatment.
- Published
- 2002
17. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder.
- Author
-
Kelleher CJ, Reese PR, Pleil AM, and Okano GJ
- Subjects
- Aged, Australia, Benzhydryl Compounds therapeutic use, Cresols therapeutic use, Delayed-Action Preparations, Double-Blind Method, Europe, Female, Health Services Research, Humans, Male, Middle Aged, Muscarinic Antagonists therapeutic use, New Zealand, Placebos, Russia, Tolterodine Tartrate, United States, Urinary Bladder Diseases drug therapy, Urinary Bladder Diseases physiopathology, Urination Disorders physiopathology, Benzhydryl Compounds administration & dosage, Cresols administration & dosage, Muscarinic Antagonists administration & dosage, Phenylpropanolamine, Quality of Life, Urination Disorders drug therapy
- Abstract
Objective: To compare the health-related quality of life (HRQoL) of overactive bladder (OAB) patients foilowing treatment with tolterodine extended-release (ER) 4 mg once daily versus placebo., Study Design: Multinational, placebo-controlled, randomized, double-blind 12-week study., Population: Patients with urinary frequency ( > or = 8 micturitions/24 hours over a 7-day period), urge incontinence ( > or = 5 episodes/week), and symptoms of OAB for at least 6 months were eligible for inclusion. Patients (81% female) received oral therapy with tolterodine ER (n = 507) or placebo (n = 508) for 12 weeks., Outcomes Measured: HRQoL was assessed using the King's Health Questionnaire (KHQ) and Medical Outcomes Study Short Form 36-item questionnaire (SF-36). Patients also rated their bladder condition. Assessments were performed at baseline and at the end of treatment., Results: At end of treatment, KHQ domains selected a priori as primary HRQoL end points (incontinence impact and role limitations) significantly improved (P < or = .001) with tolterodine ER. Domains selected a priori as secondary end points (physical limitations, sleep and energy, severity [coping] measures, and symptom severity) were also significantly improved (P < or = .006) following treatment with tolterodine ER. The tolterodine ER group had decreased symptom severity and statistically significant improvements in patient rating of bladder control compared with the placebo group at end of treatment. No treatment differences were detected using the SF-36., Conclusion: Many aspects of HRQoL, as measured by the KHQ, showed statistically significant improvement following treatment with tolterodine ER. These HRQoL improvements were consistent with clinical efficacy benefits. Patients receiving tolterodine ER experienced overall improvement in their condition that was associated with an important impact on their HRQoL.
- Published
- 2002
18. The economic impact of opioids on postoperative pain management.
- Author
-
Philip BK, Reese PR, and Burch SP
- Subjects
- Humans, Analgesics, Non-Narcotic economics, Analgesics, Non-Narcotic therapeutic use, Analgesics, Opioid adverse effects, Analgesics, Opioid economics, Hospital Charges, Pain, Postoperative drug therapy, Pain, Postoperative economics
- Abstract
Study Objective: To evaluate the consequences of opioid use for postoperative pain management and the degree to which these consequences may be reduced or minimized with opioid-sparing or opioid-replacement techniques., Design: Literature review relating to the economics of postoperative pain management. Comparisons between opioids and opioid-sparing techniques were identified and selected for study., Measurements and Main Results: Studies evaluating overall economic impacts or surrogate outcomes (e.g., resource use or recovery milestones) showed benefits with opioid-sparing therapies., Conclusions: Opioids will likely remain an integral part of postoperative pain management, but side effects increase the costs of care. The challenge is to identify situations where opioid-sparing techniques improve surrogate economic measurements and decrease overall hospital costs.
- Published
- 2002
- Full Text
- View/download PDF
19. Assessing a tool to measure patient functional ability after outpatient surgery.
- Author
-
Hogue SL, Reese PR, Colopy M, Fleisher LA, Tuman KJ, Twersky RS, Warner DS, and Jamerson B
- Subjects
- Adult, Anesthesia, General, Cognition, Female, Humans, Male, Postoperative Nausea and Vomiting, Prospective Studies, Recovery of Function, Activities of Daily Living, Ambulatory Surgical Procedures, Patient Satisfaction, Surveys and Questionnaires
- Abstract
Unlabelled: The "24-Hour Functional Ability Questionnaire" (24hFAQ) was developed to measure final recovery and satisfaction 24 h after surgery. We used structured interviews preoperatively to measure baseline patient concerns, and up to 24 h after discharge, to assess patient function and satisfaction. The primary objective was to assess the validity of the newly developed 24hFAQ in the postoperative outpatient setting. The criteria assessed were 1) CONTENT: comparison with expert opinion and patients' views and response frequency distributions for asymptotes and irrelevance, 2) Construct: contribution of cognitive, physical, and satisfaction domains to postoperative functional ability, 3) Discrimination: comparing mean clinical end points with patient satisfaction, and 4) Criterion (predictive) validity: testing that related constructs are best correlated. CONTENT validity was supported by the appropriate frequency distribution of subject responses, by the lack of floor or ceiling effects, and by <2% of responses indicating irrelevance. Construct validity was supported by moderate-to-strong positive interitem correlations within the cognitive and physical domains as predicted a priori. Discriminant validity support was mixed: key symptoms were associated with adverse patient satisfaction, but operating room and postanesthesia care unit residence times were unrelated. Criterion validity was supported by the finding that preoperative concern with key symptoms was independent of postoperative outcomes. The validity assessment presented was the first assessment of the measurement capability of the 24hFAQ in an outpatient postoperative population. These results provide overall support for the validity of the 24hFAQ for use in outpatient populations., Implications: This study assessed the validity of a novel functional ability questionnaire that measured functional status after recovery from anesthesia and satisfaction 24 h after outpatient surgery. The content, construct, discriminant, and criterion (predictive) validities demonstrated the utility of this assessment instrument in the outpatient setting.
- Published
- 2000
- Full Text
- View/download PDF
20. Cost analysis of remifentanil and fentanyl for neurosurgical anesthesia.
- Author
-
Hogue S, Reese PR, Munshi O, and Young T
- Subjects
- Craniotomy, Double-Blind Method, Humans, North Carolina, Remifentanil, Retrospective Studies, Analgesics, Opioid economics, Anesthetics, Intravenous economics, Fentanyl economics, Hospital Costs, Piperidines economics, Supratentorial Neoplasms surgery
- Published
- 1999
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.